{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Calculation of the risk score requires that the patient be assessed with the CALGB Assessment Tool, which has both a patient self-reporting questionnaire and a clinician assessment. Both will be used in this trial, and thus patients will have risk scores based on their own self-assessments and risk scores based on the clinicians' assessment. The risk score ranges from 0-19, with 0-5 indicating low risk, 6-9 intermediate risk, and 10-19 high risk. The distribution of the risk score in this trial will be described by plotting the median of the risk score against time, with patient and clinician assessments overlaid on the same plot.","groups":[{"description":"INDUCTION (28-day cycles for 8 cycles):\n\n* VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15\n* Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15\n* Dexamethasone 40 mg PO days 1,8 and 15\n\nMAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):\n\n* Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21\n* Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15\n\nVelcade: Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles \\[10,12,14, etc.\\]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until","id":"OG000","title":"Velcade, Cyclophosphamide, Revlimid"}],"populationDescription":"Data for the risk score wasn't recorded correctly, and therefore we were unable to analyze the data.","reportingStatus":"POSTED","timeFrame":"Day 1","title":"Risk Score as Assessed Using the Cancer and Leukemia Group B (CALGB) Geriatric Assessment Tool","type":"SECONDARY"}